drug
semaglutide
Preclinicalupdated 3mo agoby BioLingus AG
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 8- drugOzempic120 co-mentions · 72 sources
- drugWegovy120 co-mentions · 72 sources
- drugWegovy Pill94 co-mentions · 72 sources
- tagApproval88 co-mentions · 44 sources
- drugRybelsus72 co-mentions · 72 sources
- tagRecall29 co-mentions · 27 sources
- tagSmall Molecule17 co-mentions · 17 sources
- companyNovo Nordisk Inc10 co-mentions · 3 sources
all catalysts(0)
nothing on the calendar yet
Trials studying semaglutide
- phase3A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes
- phase1A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes
- phase3A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- phase3A Study of BGM0504 in Early T2DM With Obesity
- phase2Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
- phase3A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
- phase4Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
- phase1Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
News(10)
- Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.biospace · 1d ago
- Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemiaWith a Phase 3 trial showing a reduction of serious and severe hypoglycemic episodes in patients who have undergone weight loss surgery, Amylyx Pharmaceuticals plans to file for approval this year.…biospace · 1d ago
- Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 winAmylyx Pharmaceuticals’ $35 million bet on the GLP-1 receptor antagonist avexitide appears to have paid off, with the molecule cutting the number of dangerous blood sugar crashes by more than half…fiercebiotech · 2d ago
- Skye and Redx form new entity with $125M to advance fibrosis assetsSkye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new public company, calle…fiercebiotech · 5d ago
- Lilly, FDA retatrutide biologic dispute comes to a head as submission nearsA legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicin…biospace · 14d ago
- Novo CEO sees innovation as a matter of survival amid pipeline setbacksNovo Nordisk CEO Maziar Mike Doustdar on a second quarter earnings call argued that failure is par for the course in the drug development business. The Danish pharma is focused on building out its…biospace · 14d ago
- ‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growthNovo Nordisk CFO Karsten Munk Knudsen spoke to Fierce the morning the company unveiled its second-quarter earnings, reflecting on Novo’s “roller coaster” financial journey, the pressure of navigati…fiercebiotech · 14d ago
- Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed dataNovo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is…fiercebiotech · 15d ago
- FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s dataReplimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result.biopharma_dive · 21d ago
- Novo ordered to face CagriSema fraud claims from shareholders: New Jersey courtShareholders allege that Novo Nordisk withheld information about crucial protocol changes in a Phase 3 study of the weight loss drug CagriSema, which led investors to buy company shares “at artific…biospace · 21d ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that